Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more
Gilead Sciences Inc (GILD) - Net Assets
Latest net assets as of December 2025: $22.62 Billion USD
Based on the latest financial reports, Gilead Sciences Inc (GILD) has net assets worth $22.62 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($59.02 Billion) and total liabilities ($36.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.62 Billion |
| % of Total Assets | 38.32% |
| Annual Growth Rate | 24.84% |
| 5-Year Change | 5.63% |
| 10-Year Change | 0.7% |
| Growth Volatility | 157.92 |
Gilead Sciences Inc - Net Assets Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gilead Sciences Inc (1990–2024)
The table below shows the annual net assets of Gilead Sciences Inc from 1990 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $19.25 Billion | -15.40% |
| 2023-12-31 | $22.75 Billion | +7.26% |
| 2022-12-31 | $21.21 Billion | +0.69% |
| 2021-12-31 | $21.06 Billion | +15.60% |
| 2020-12-31 | $18.22 Billion | -19.55% |
| 2019-12-31 | $22.65 Billion | +5.18% |
| 2018-12-31 | $21.53 Billion | +5.04% |
| 2017-12-31 | $20.50 Billion | +5.88% |
| 2016-12-31 | $19.36 Billion | +1.31% |
| 2015-12-31 | $19.11 Billion | +20.82% |
| 2014-12-31 | $15.82 Billion | +34.69% |
| 2013-12-31 | $11.74 Billion | +23.07% |
| 2012-12-31 | $9.54 Billion | +38.97% |
| 2011-12-31 | $6.87 Billion | +12.18% |
| 2010-12-31 | $6.12 Billion | -5.89% |
| 2009-12-31 | $6.51 Billion | +45.67% |
| 2008-12-31 | $4.47 Billion | +24.03% |
| 2007-12-31 | $3.60 Billion | +92.65% |
| 2006-12-31 | $1.87 Billion | -38.28% |
| 2005-12-31 | $3.03 Billion | +61.84% |
| 2004-12-31 | $1.87 Billion | +86.53% |
| 2003-12-31 | $1.00 Billion | +75.55% |
| 2002-12-31 | $571.34 Million | +26.28% |
| 2001-12-31 | $452.44 Million | +28.85% |
| 2000-12-31 | $351.12 Million | +18.11% |
| 1999-12-31 | $297.29 Million | -10.91% |
| 1998-12-31 | $333.70 Million | +5.17% |
| 1997-12-31 | $317.30 Million | +8.78% |
| 1996-12-31 | $291.70 Million | +92.54% |
| 1995-12-31 | $151.50 Million | +75.96% |
| 1994-12-31 | $86.10 Million | -25.33% |
| 1993-12-31 | $115.30 Million | -17.29% |
| 1992-12-31 | $139.40 Million | +32.01% |
| 1991-12-31 | $105.60 Million | +935.29% |
| 1990-12-31 | $10.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gilead Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1150680000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.50 Billion | 59.48% |
| Common Stock | $1.00 Million | 0.01% |
| Other Comprehensive Income | $132.00 Million | 0.68% |
| Other Components | $7.70 Billion | 39.83% |
| Total Equity | $19.33 Billion | 100.00% |
Gilead Sciences Inc Competitors by Market Cap
The table below lists competitors of Gilead Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Novo Nordisk A/S
PINK:NONOF
|
$175.04 Billion |
|
Walt Disney Company
NYSE:DIS
|
$175.86 Billion |
|
0QZO
LSE:0QZO
|
$176.18 Billion |
|
Salesforce.com Inc
NYSE:CRM
|
$177.17 Billion |
|
Siemens Aktiengesellschaft
XETRA:SIE
|
$174.65 Billion |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
$174.19 Billion |
|
TJX Cos.
LSE:0LCE
|
$174.02 Billion |
|
HSBC Holdings PLC
PINK:HBCYF
|
$173.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gilead Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,833,000,000 to 19,330,000,000, a change of -3,503,000,000 (-15.3%).
- Net income of 480,000,000 contributed positively to equity growth.
- Dividend payments of 3,918,000,000 reduced retained earnings.
- Share repurchases of 1,150,000,000 reduced equity.
- New share issuances of 422,000,000 increased equity.
- Other comprehensive income increased equity by 104,000,000.
- Other factors increased equity by 559,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $480.00 Million | +2.48% |
| Dividends Paid | $3.92 Billion | -20.27% |
| Share Repurchases | $1.15 Billion | -5.95% |
| Share Issuances | $422.00 Million | +2.18% |
| Other Comprehensive Income | $104.00 Million | +0.54% |
| Other Changes | $559.00 Million | +2.89% |
| Total Change | $- | -15.34% |
Book Value vs Market Value Analysis
This analysis compares Gilead Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4221.55x to 9.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.03 | $141.29 | x |
| 1991-12-31 | $0.29 | $141.29 | x |
| 1992-12-31 | $0.27 | $141.29 | x |
| 1993-12-31 | $0.19 | $141.29 | x |
| 1994-12-31 | $0.14 | $141.29 | x |
| 1995-12-31 | $0.22 | $141.29 | x |
| 1996-12-31 | $0.33 | $141.29 | x |
| 1997-12-31 | $0.31 | $141.29 | x |
| 1998-12-31 | $0.25 | $141.29 | x |
| 1999-12-31 | $0.22 | $141.29 | x |
| 2000-12-31 | $0.24 | $141.29 | x |
| 2001-12-31 | $0.28 | $141.29 | x |
| 2002-12-31 | $0.35 | $141.29 | x |
| 2003-12-31 | $0.62 | $141.29 | x |
| 2004-12-31 | $1.01 | $141.29 | x |
| 2005-12-31 | $1.60 | $141.29 | x |
| 2006-12-31 | $0.99 | $141.29 | x |
| 2007-12-31 | $1.79 | $141.29 | x |
| 2008-12-31 | $2.23 | $141.29 | x |
| 2009-12-31 | $3.41 | $141.29 | x |
| 2010-12-31 | $3.36 | $141.29 | x |
| 2011-12-31 | $4.26 | $141.29 | x |
| 2012-12-31 | $5.88 | $141.29 | x |
| 2013-12-31 | $6.71 | $141.29 | x |
| 2014-12-31 | $9.60 | $141.29 | x |
| 2015-12-31 | $12.57 | $141.29 | x |
| 2016-12-31 | $14.26 | $141.29 | x |
| 2017-12-31 | $15.50 | $141.29 | x |
| 2018-12-31 | $16.35 | $141.29 | x |
| 2019-12-31 | $17.64 | $141.29 | x |
| 2020-12-31 | $14.41 | $141.29 | x |
| 2021-12-31 | $16.69 | $141.29 | x |
| 2022-12-31 | $16.83 | $141.29 | x |
| 2023-12-31 | $18.15 | $141.29 | x |
| 2024-12-31 | $15.40 | $141.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gilead Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.67%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 3.05x
- Recent ROE (2.48%) is below the historical average (13.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -39.22% | -307.69% | 0.10x | 1.23x | $-5.02 Million |
| 1991 | -4.26% | -160.71% | 0.03x | 1.03x | $-15.06 Million |
| 1992 | -10.11% | -335.71% | 0.03x | 1.05x | $-28.04 Million |
| 1993 | -22.29% | -626.83% | 0.03x | 1.10x | $-37.23 Million |
| 1994 | -36.35% | -638.78% | 0.05x | 1.19x | $-39.91 Million |
| 1995 | -18.09% | -1014.81% | 0.02x | 1.10x | $-42.55 Million |
| 1996 | -7.44% | -64.97% | 0.11x | 1.07x | $-50.87 Million |
| 1997 | -22.98% | -55.10% | 0.38x | 1.11x | $-104.63 Million |
| 1998 | -13.43% | -29.65% | 0.31x | 1.46x | $-78.17 Million |
| 1999 | -22.37% | -39.35% | 0.39x | 1.47x | $-96.23 Million |
| 2000 | -16.17% | -29.03% | 0.29x | 1.93x | $-91.89 Million |
| 2001 | 11.55% | 22.36% | 0.29x | 1.76x | $7.03 Million |
| 2002 | 12.62% | 15.45% | 0.36x | 2.25x | $14.96 Million |
| 2003 | -7.18% | -8.30% | 0.56x | 1.55x | $-172.30 Million |
| 2004 | 24.02% | 33.92% | 0.61x | 1.15x | $262.28 Million |
| 2005 | 26.88% | 40.13% | 0.54x | 1.24x | $511.14 Million |
| 2006 | -65.54% | -39.32% | 0.74x | 2.25x | $-1.37 Billion |
| 2007 | 46.69% | 38.19% | 0.72x | 1.69x | $1.27 Billion |
| 2008 | 46.32% | 37.09% | 0.77x | 1.62x | $1.55 Billion |
| 2009 | 41.40% | 37.59% | 0.72x | 1.52x | $2.00 Billion |
| 2010 | 49.48% | 36.50% | 0.69x | 1.98x | $2.31 Billion |
| 2011 | 41.60% | 33.43% | 0.48x | 2.57x | $2.13 Billion |
| 2012 | 27.86% | 26.72% | 0.46x | 2.28x | $1.66 Billion |
| 2013 | 27.04% | 27.45% | 0.50x | 1.99x | $1.94 Billion |
| 2014 | 76.50% | 48.62% | 0.72x | 2.19x | $10.52 Billion |
| 2015 | 94.74% | 55.48% | 0.63x | 2.71x | $16.20 Billion |
| 2016 | 69.73% | 44.43% | 0.53x | 2.94x | $11.56 Billion |
| 2017 | 22.64% | 17.73% | 0.37x | 3.44x | $2.58 Billion |
| 2018 | 25.51% | 24.65% | 0.35x | 2.98x | $3.32 Billion |
| 2019 | 23.91% | 23.99% | 0.36x | 2.74x | $3.13 Billion |
| 2020 | 0.68% | 0.50% | 0.36x | 3.76x | $-1.70 Billion |
| 2021 | 29.55% | 22.80% | 0.40x | 3.23x | $4.12 Billion |
| 2022 | 21.62% | 16.83% | 0.43x | 2.97x | $2.47 Billion |
| 2023 | 24.81% | 20.89% | 0.44x | 2.72x | $3.38 Billion |
| 2024 | 2.48% | 1.67% | 0.49x | 3.05x | $-1.45 Billion |
Industry Comparison
This section compares Gilead Sciences Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $234,331,063,830
- Average return on equity (ROE) among peers: 24.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gilead Sciences Inc (GILD) | $22.62 Billion | -39.22% | 1.61x | $174.91 Billion |
| AbbVie Inc (ABBV) | $17.29 Billion | 68.47% | 7.03x | $367.74 Billion |
| Astellas Pharma Inc (ALPMF) | $1.29 Trillion | 15.16% | 0.80x | $16.93 Billion |
| Amgen Inc (AMGN) | $5.22 Billion | 21.46% | 0.23x | $188.97 Billion |
| Amarin Corporation PLC (AMRN) | $595.33 Million | -17.77% | 0.49x | $303.32 Million |
| AstraZeneca PLC (AZN) | $19.65 Billion | 6.28% | 1.98x | $290.81 Billion |
| Bayer AG (BAYZF) | $16.08 Billion | 2.21% | 3.55x | $21.61 Billion |
| Biogen Inc (BIIB) | $74.90 Million | -25.50% | 0.15x | $26.68 Billion |
| Bristol-Myers Squibb Company (BMY) | $15.24 Billion | 16.82% | 1.53x | $120.67 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $980.00 Billion | 21.91% | 0.26x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $631.00K | 132.81% | 43.71x | $529.97 Million |